Lantheus (NASDAQ:LNTH – Get Rating) updated its FY 2022 earnings guidance on Thursday. The company provided earnings per share guidance of $3.50-$3.60 for the period, compared to the consensus earnings per share estimate of $3.08. The company issued revenue guidance of $885.00 million-$905.00 million, compared to the consensus revenue estimate of $829.39 million. Lantheus also updated its Q3 2022 guidance to $0.80-$0.85 EPS.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. B. Riley assumed coverage on shares of Lantheus in a research report on Monday, May 9th. They set a buy rating and a $91.00 price objective for the company. SVB Leerink upped their target price on shares of Lantheus from $100.00 to $110.00 and gave the stock an outperform rating in a report on Friday. Finally, Truist Financial upped their target price on shares of Lantheus from $77.00 to $94.00 in a report on Monday, May 2nd.

Lantheus Price Performance

Shares of NASDAQ LNTH traded up $7.33 during mid-day trading on Friday, hitting $78.57. 1,703,905 shares of the company's stock traded hands, compared to its average volume of 1,357,643. The company's 50-day moving average is $67.85 and its two-hundred day moving average is $55.77. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.85 and a quick ratio of 1.64. The company has a market capitalization of $5.39 billion, a P/E ratio of 182.72 and a beta of 0.79. Lantheus has a 1 year low of $22.20 and a 1 year high of $81.43.

Insider Buying and Selling

In related news, CEO Mary Anne Heino sold 12,276 shares of the stock in a transaction dated Monday, May 9th. The shares were sold at an average price of $61.19, for a total value of $751,168.44. Following the sale, the chief executive officer now directly owns 695,115 shares of the company's stock, valued at approximately $42,534,086.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Lantheus news, insider Daniel Niedzwiecki sold 1,380 shares of the company's stock in a transaction dated Wednesday, May 18th. The shares were sold at an average price of $64.54, for a total value of $89,065.20. Following the transaction, the insider now directly owns 71,143 shares in the company, valued at approximately $4,591,569.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Mary Anne Heino sold 12,276 shares of the company's stock in a transaction dated Monday, May 9th. The stock was sold at an average price of $61.19, for a total transaction of $751,168.44. Following the completion of the transaction, the chief executive officer now owns 695,115 shares in the company, valued at $42,534,086.85. The disclosure for this sale can be found here. Insiders have sold 26,798 shares of company stock valued at $1,676,307 in the last ninety days. 1.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently modified their holdings of LNTH. Fairfield Bush & CO. bought a new position in shares of Lantheus during the first quarter valued at approximately $177,000. Mackenzie Financial Corp bought a new position in shares of Lantheus during the first quarter valued at approximately $212,000. Pearl River Capital LLC purchased a new stake in Lantheus during the first quarter valued at approximately $226,000. First Republic Investment Management Inc. purchased a new stake in Lantheus during the first quarter valued at approximately $228,000. Finally, PNC Financial Services Group Inc. lifted its position in Lantheus by 30.3% during the first quarter. PNC Financial Services Group Inc. now owns 4,721 shares of the medical equipment provider's stock valued at $261,000 after acquiring an additional 1,099 shares during the last quarter. 97.14% of the stock is currently owned by institutional investors.

About Lantheus

(Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Read More

• Get a free copy of the StockNews.com research report on Lantheus (LNTH)
• MarketBeat: Week in Review 8/1 – 8/5
• How to Use High Beta Stocks to Maximize Your Investing Profits
• Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
• Beyond Meat Is Not Beyond Hope, And It's Cheap
• Why Apple Could Be At All-Time Highs By Year End

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.